ucsf logo

Bridget Keenan, MD, PhD

She | Her | Hers
Cancer Immunotherapy Mission Bay
415-353-2051
Portrait of Bridget Keenan
Portrait of Bridget Keenan
ucsf logo

Bridget Keenan, MD, PhD

She | Her | Hers
Cancer Immunotherapy Mission Bay
415-353-2051

On this page

About me

Dr. Bridget Keenan is an oncologist and physician-scientist, a doctor particularly focused on research. She cares for patients with solid organ tumors who are seeking or enrolled in immunotherapy clinical trials (studies of promising new treatments). She has a special interest in digestive system cancers.

Keenan's research investigates various immunotherapy approaches to fighting cancer, including checkpoint inhibitors (drugs that prevent an immune system response that may otherwise allow cancer cells to evade destruction), cellular therapies, bispecific antibodies (parts of lab-produced antibodies that bind to T cells and tumors so that cancer cells are directly targeted) and other new treatments.

Keenan earned her medical degree and a doctorate in immunology at the Johns Hopkins University School of Medicine. At UCSF, she completed a residency in internal medicine and a fellowship in hematology and oncology.

Education & training

Board certification

  • Medical Oncology, American Board of Internal Med/Medical Oncology

Fellowship

  • Hematology - Oncology, University of CA at San Francisco School of Med

Residency

  • Internal Medicine, University of CA at San Francisco School of Med

Internship

  • Internal Medicine, University of CA at San Francisco School of Med

Degree

  • MD, Johns Hopkins University School of Medicine

Locations

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.